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Comparison between immunocytochemical and polymerase chain reaction
techniques for detection of oestrogen receptor and transforming growth
factor in breast cancer
KD Amoils, L Seymour and WR Bezwoda
Department of Medicine, University of the Witwatersrand, 7 York Road, Parktown 2193, South Africa.
Summary The utility of the polymerase chain reaction (PCR) as a technique for determining the expression of
transforming growth factor ,B (TGF-fl) and of the oestrogen receptor (ER) in clinical breast cancer tissue was
examined. PCR analysis was compared with immunocytochemical assays for TGF-,B and for ER. Seventy
confirmed breast carcinoma samples were analysed for ER using both techniques with a statistically highly
significant concordance (P<0.001) between the two methods. Nineteen samples were observed to be ER
positive and 46 samples were found to be ER negative by both techniques. Forty-eight samples were analysed
for TGF-,B using both PCR and immunocytochemistry. Of the 24 samples observed to be positive for TGF-,B
by immunocytochemistry, all were found to be positive for TGF-,B mRNA (PCR). Similarly, the 24 samples
observed to be TGF-,B negative by immunocytochemistry were also negative for TGF-fl mRNA, indicating
100% specificity and 100% sensitivity of the PCR technique. PCR is therefore considered a viable technique for
analysis of both ER and TGF-,B in small samples such as fine-needle aspirates.
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The oestrogen receptor (ER) content of human breast cancer
has been found to be a significant prognostic factor in early
breast cancer (Cooke et al., 1979; Knight et al., 1977;
Maynard et al., 1978; De Sombre et al., 1979) as well as
being a predictor of hormone responsiveness in patients with
advanced disease (Paridaens et al., 1980; Dao and Nemoto,
1980; Lippman and Allegra, 1980; Osborne et al., 1980; Rose
et al., 1985; Glauber and Kiang, 1992). The first reliable and
reproducible assays to be developed for ER in breast cancer
extracts were ligand-binding assays (RLBAs) using radiola-
belled specific ligands such as [3H]17-fl-oestradiol together
with various techniques such as dextose-coated charcoal
(Korenman and Dukes, 1970; McGuire et al., 1975; Wittliff,
1984) or sucrose gradient sedimentation (Wittliff, 1979) to
separate bound and free steroid.
The availability of specific antibodies to ER, as
demonstrated by King and Green (1984), provided the
opportunity to determine the presence of receptor proteins
by immunoassay methods. The advantages of the ER
immunoassay (ERICA) over the ligand-binding assays
include greater ease of specimen collection and storage as
well as obviating the need for radioactive isotope handling.
Immunocytochemistry is rapid and can be performed on
much smaller samples, including cytological preparations
obtained by fine-needle aspiration. Although such immuno-
logical assays have been found to correlate well with RLBAs
(King et al., 1985; De Sombre et al., 1986; Jonat et al., 1986;
McCarty et al., 1986), there is a subjective component to the
interpretation of results unless advanced image-analysing
systems are used. Moreover, the technique does not lend itself
to the analysis of multiple prognostic determinants unless a
large number of histological or cytological sections are
unavailable.
The cellular effects of hormones or drugs that can
specifically bind to ER and either induce or block
oestrogen-mediated effects has been shown to be indirect,
through triggering of growth factor transcription, translation
and release. One of the more important of these factors,
modulating the growth of cells, is thought to be transforming
growth factor # (TGF-f,). The TGF-,Bs constitute a family of
transforming growth factors which have been implicated in
the control of proliferation of breast cancer cells (Knabbe et
al., 1987). TGF-# has been detected by immunocytochemical
techniques in a number of tissues (Hirayama et al., 1992) and
also by in situ hybridisation techniques in embryonic tissues
(Pelton et al., 1990). It has been suggested that the growth of
human breast tumours may be influenced by autocrine
secretion of TGF-fi (Roberts et al., 1988) and altered
expression, in cancer cells, of TGF-,Bs in cancers has been
reported (Barrett-Lee et al., 1990). The relationship of TGF-f
and ER expression has not, however, been studied extensively
in clinical breast cancer.
The aim of this study was to investigate PCR as a tool for
the detection of ER and TGF-,B in breast cancer.
Materials and methods
Tissue samples
Samples were obtained from breast masses, clinically
suspected of being breast cancer, from 115 patients, either
by fine-needle aspiration or by needle biopsy. Fine-needle
aspirates (FNAs) were obtained by multiple needle passes
with a 21 g needle attached to a 10 ml syringe. The needle
contents were then expelled into and the needles rinsed five
times in 0.5 ml of 50% ethanol in a microfuge tube. An
aliquot of each FNA sample was submitted for cytological
examination while biopsy samples were submitted for routine
paraffin-fixed, haematoxylin- and eosin-stained, histological
examination in order to confirm that the material contained
tumour cells. The aliquots used for PCR analysis were stored
at -700C in the 50% ethanol. Needle biopsies were
performed using a Tru-Cut needle (Travenol Labs., Deer-
field, IL, USA). A portion of each needle biopsy sample was
fixed in 50% ethanol and stored at -70°C.
ER immunocytochemistry
Needle biopsy specimens for immunocytochemical assay of
ER were teased onto HCl-ethanol-cleaned slides and
immediately fixed in 4% formalin for 10 min, rinsed in
phosphate-buffered saline (PBS), dipped sequentially in ice-
cold methanol and acetone and rinsed again in PBS.
Cytospin preparations were made from FNA samples and
fixed in identical fashion. ER immunocytochemistry was
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performed using the ERICA kit from Abbott Laboratories
according to the manufacturers instructions. The ERICA kit
contains both positive and negative controls. Both intensity
of immunostaining and the number of cells stained were
included in the assessment. All cells on the slides were
examined, but specimens had to contain a minimum of 20
intact tumour cells to be deemed evaluable by ERICA.
ERICA positive samples were defined as those having H-
score >40, which in previous studies from this laboratory
has been found to correlate with ER content, by dextan-
coated charcoal assay, of >30 fmol mg-' protein (Seymour
et al., 1990).
TGF-# immunocytochemical assay
Tissue specimens for TGF-f immunocytochemistry were
teased onto hydrochloric acid-ethanol-cleaned slides, im-
mediately fixed in a modification of Bouins fluid (Stefanini et
al., 1967) for 15 min and washed twice in PBS. Cytospin
preparations were made from FNA samples and also fixed in
modified Bouins fluid. Endogenous peroxidase activity was
blocked with methanol-hydrogen peroxide for 30 min. The
slides were rinsed in PBS and incubated at room temperature
with goat serum for 20 min followed by a 3 h incubation with
monospecific, polyclonal, rabbit-anti-human TGF-f (British
Biotechnology Ltd, Oxford, UK) as the primary antibody at
a concentration of 20 jug ml-'. After briefly washing in PBS
biotinylated secondary antibody (goat anti-rabbit) was
applied at a 1:200 dilution. The reaction was developed
with diaminobenzidine, the slides were counterstained with
Meyer's haematoxylin, serially dehydrated, mounted with
coverslips and examined under 400 x magnification. Positive
controls included MCF-7 cells [American Tissue Culture
Collection, (ATCC) HTB 22], which were maintained in
Dulbecco's modified Eagle medium (DMEM) and 5% fetal
calf serum (FCS) and A549 cells (ATCC CCL 185), which
were maintained in DMEM and 10% FCS. A negative
control followed all the steps outlined but used 1% bovine
serum albumin (BSA) in PBS instead of the specific primary
antibody.
RNA extraction
Total RNA was extracted using guanidinium thiocyanate-
phenol-chloroform according to Chomczynski and Sacchi
(1987). The final RNA extract was dissolved in diethylpyro-
carbonate-treated water and stored at -70°C until reverse
transcribed.
Reverse transcription
Total RNA (2 pl) was converted into cDNA by reverse
transcription using 15 of units avian myeloblastosis virus
(AMV) reverse transcriptase (Promega, USA) in the presence
of 1.33 pmol of oligo(dT)15 primer (Boehringer-Mannheim,
West Germany) and 1 mM of each dNTP in a buffer
containing 10 mM Tris-HCl, pH 8.3, 50 mM potassium
chloride, 10 mg ml-' gelatin and 5 mM magnesium chloride
in a total volume of 30 pl. The reaction was incubated at
37°C for 1 h followed by incubation at 95°C for 5 min to
inactivate the enzyme. Sterile water was used in place of
RNA as a negative control.
Polymerase chain reaction (PCR)
cDNA was amplified by PCR using specific oligonucleotide
primers designed to detect the target cDNA (Table I). The
reaction was carried out in a total volume of 50 Mil consisting
of cDNA preparation (30 Ml), reaction buffer (10 mM Tris-
HCl, pH 8.3, 50 mM potassium chloride and 0.1% gelatin),
1 mM magnesium chloride (for TGF-,B PCR only), 1 gM
forward (5') primer, 0.5 gM reverse (3') primer and 1 unit of
Taq polymerase (Boehringer-Mannheim, West Germany).
Amplification was performed for 30 cycles in a program-
Table I Primer sequences
Primer Sequence Product size
ER 5' TCTGAGGCTGCGGCGTT 427 bp
ER3' GGTTGGTGGCTGGACACA
TGF-,B 5' GCCCTGGACACCACCTATTGCT 161 bp
TGF-,B 3' AGGCTCCAAATGTAGGGGCAGG
Allprimer sequences givenin 5' to 3' orientation. TheTGF-,Bprimer
is specific for thePlI TGF-f, isoform.
mable Thermal Cycler (Hybaid, UK). The cycle conditions in
the presence of 50 MI of mineral oil were as follows:
* ER. Denaturation at 94°C for 1 min (960C for 10 min in
the initial cycle), annealing at 540C for 1 min and extension
at 72°C for 1 min with a final extension at 720C for 5 min.
* TGF-fl. Denaturation at 94°C for 1 min (960C for 10 min
in the initial cycle), annealing at 630C for 1 min and
extension at 72°C for 1 min with a final extension at 720C
for 7 min.
The reaction products of PCR were analysed by
electrophoresis on 2% agarose gels (Promega), containing
0.5 mg ml-' ethidium bromide.
Southern blotting
The agarose gels were incubated for 45 min in 0.5 M sodium
hydroxide, 1.5 M sodium chloride, and twice for 30 min in
1 M Tris-HCl, pH 7.4, 1.5 M sodium chloride. Nucleic acids
were transferred for 16 h to nylon membranes (Hybond-N,
Amersham, UK), the membranes were washed in 10x SSC
(10 x SSC= 1.5M sodium chloride, 0.15 M sodium citrate), air
dried for 30 min and fixed by baking at 80°C for 1 h under
vacuum.
Hybridisation with radioactive probes
The plasmid clone, pOR3 (ATCC 57680), with the cDNA
insert containing nucleotides 300-1600 of the ER gene
(Green et al., 1986), was obtained from the ATCC. The
probe insert was released by digestion with EcoRI restriction
enzyme (Boehringer-Mannheim, Germany) and treated by
random priming (Random Primed DNA Labelling Kit,
Boehringer-Mannheim, Germany) using [32P] dCTP (3000
Ci mmol-') (Amersham, UK). Similarly, the phTGB-2
(ATCC 59954) plasmid clone, containing the cDNA insert
including the complete coding sequence of TGF-f,l, was
digested with EcoRI to release the probe and labelled using
the random primed DNA labelling kit with [32P]-dCTP.
The membranes were prehybridised for 24 h at 420C in
5 x SSC, 50% deionised formamide, 5 x Denhardt's solution
(50 x solution= 1% Ficoll, 1% polyvinylpyrrolidone and 1%
BSA), 0.5% sodium dodecyl sulphate (SDS), 100 Mg ml-'
denatured herring sperm DNA. Hybridisation was performed
for 24 h at 42°C in the same buffer but without SDS and
with the relevant 32P-labelled probe. The membranes were
washed for 5 min in 2 x SSC, 0.5% SDS at room temperature
and for 25 min in 2 x SSC, 0.1% SDS, at room temperature.
Autoradiography was performed at -700C for 48 h with
Hyperfilm-MP (Amersham, UK) with intensifying screens.
Validation of PCR products
Specific PCR products were considered to be present if clean
products of the predicted size were obtained after amplifica-
tion. Primers were selected to bridge intron-exon boundaries
therefore excluding the presence of contaminating genomic
DNA (the product would be larger than predicted if gDNA
was present). Positive and negative controls were run
simultaneously with negative controls producing no PCR
product. Further confirmation was obtained by usingImmunocytochemistry and PCR and ER and TGF-f
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Southern blotting and hybridisation with specific radiola-
belled probes. Comparison of the results with the two
methods was by chi-square analysis.
The study was performed according to the principles of
the Declaration of Helsinki and was approved by the
Committee for Ethics of Human Research of the University
of the Witwatersrand.
Results
Of the 115 samples analysed, 26 were found not to contain
any malignant cells by cytological and/or histological
evaluation. Of these 25, there were nine cases of
fibroadenosis, another six samples in which only fat cells
were identified by cytological examination, six that were
acellular and another five that contained only blood and/or
inflammatory cells. PCR analysis was nevertheless carried out
using this material with uniformly negative results for both
ER and TGF-f mRNA expression. These samples thus form
an important control group over and above the reagent
blanks used for each of the PCR procedures.
Of the remaining 89 samples in which tumour cells were
detected, there was sufficient material for ER determination
by both immunochemistry and by the PCR method in 70.
Details of these 70 patients are given in Table II. Nineteen
out of 70 (27%) were found to be ER positive and 46/70
(66%) were ER negative by both techniques with a P-value
of <0.001 (Table III). Four patients (6%) were observed to
be ER positive by ERICA but ER negative by PCR and one
sample, which was analysed as ER positive by PCR, was
considered ER negative by ERICA.
Forty-eight samples were analysed for TGF-,B by both
PCR and immunocytochemistry with 24/48 (50%) being
TGF-P positive and 24/48 (50%) showing TGF-,B negative by
both techniques (Table IV) indicating 100% specificity and
100% sensitivity.
Further investigation of the sensitivity of these methods
for detection of ER and TGF-fB in samples containing only
Table II Patient and tumour characteristics
Characteristic Frequency (%)
Patients Total number
Age in years
Mean
Range
Menopausal status
Premenopausal
Post-menopausal
Race
Black
Caucasian
Tumours Size (cm)
Tl (<2)
T2 (2-5)
T3 (>5)
T4
Nodal status
NO
NI
N2
Metastases
MO
Ml
Histology
Infiltrating duct
Lobular
Other
Stage
I
II
III
IV
70
51.7
27-83
30 (43)
40 (57)
42 (60)
28 (40)
9 (13)
38 (54)
10 (14)
13 (19)
14 (20)
56 (80)
0 (0)
42 (60)
28 (40)
59 (84)
7 (10)
4 (6)
11(16)
27 (38)
4 (6)
28 (40)
scanty cell material showed that both ER and TGF-# mRNA
could be reliably detected in samples containing as little as
1000 cells per 0.5 ml. No significant differences were found
when the frequency of ER expression in Tru-Cut needle
biopsy samples (13 specimens, 4/13 ER+ by both techniques)
were compared with FNA samples (16/57, 28% ER+ by
PCR and 19/57, 33%, ER+ by ERICA).
Discussion
The present study validates PCR as a viable method of
detecting expression of ER mRNA from small samples such
as FNAs. Out of a total of 70 patients analysed for ER by
both PCR and ERICA, 94% of the samples exhibited the
same results.
While specificity appears to be good, some attention has to
be paid to the question of the sensitivity of the method. Only
70 of the 89 samples could be analysed by both techniques. It
should, however, be noted that in all instances in which there
was not sufficient material to perform both assays, the
difficulty lay in obtaining enough cells for ERICA. All 89
samples containing tumour cells were able to be analysed by
PCR with a detection of ER mRNA in 23/89 (26%).
A further consideration regarding the sensitivity of these
assays is whether or not they accord with the patient
population studied. The frequency of ER expression is
known to vary with menstrual status and age (Thorpe et
al., 1987) as well as with ethnic origin (Levin et al., 1978;
Pegoraro et al., 1986) and is, moreover, an indicator of
disease biology (Maynard et al., 1978; Clark et al., 1984). In
this regard, it should be noted that the mean age of the
patient included in this study was 52 years, 43% were
premenopausal, 60% were black and 40% presented with
stage 4 disease. For the population studied, the expected
frequency of ER expression would appear to be in the range
observed in the current investigation.
While the two techniques were concordant in most
instances, there were a few discrepant results using the two
methods. Four (6%) samples showed positive ER protein
expression (ERICA) but no mRNA expression (PCR). One
possible explanation for this finding would be a mutation
within the chosen primer regions resulting in a failure to
detect the appropriate PCR product. The segment of ER
mRNA chosen for amplification by PCR in this study was
located predominantly in the DNA-binding domain, while
the specificity of the monoclonal antibody used for the
Table III Comparison between mRNA expression (PCR) and
protein expression (ERICA) as methods for detection of ER
ERmRNA positive ERmRNA negative Total
ERICA + 19 4 23
ERICA- 1 46 47
Total 20 50 70
P<0.001.
Table IV Comparison between mRNA expression (PCR) and
protein expression (immunocytochemistry) as measurements of
TGF-,B
TGF-f immunocytochemistry
Positive Negative Total
TGF-,B mRNA + 24 0 24
TGF-,B mRNA- 0 24 24
Total 24 24 24
P<0.001.
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immunochemical methods is against epitopes in the hormonal
binding region of the molecule. Fuqua et al. (1993) have,
identified an alternatively spliced ER variant missing exon 3
of the DNA-binding domain. A normal ER sequence was
observed in the variant until the exon 2-intron border,
where exon 2 was then joined to exon 4. As the reverse
primer used in our study was located between positions 1009
and 1026 within exon 3 (Green et al., 1986; Ponglikitmongkol
et al., 1988) the presence of such a variant could result in
negative findings by PCR analysis. Although exon 3 is known
to encode the second zinc finger of the receptor, which is
required for DNA binding, Fuqua et al. (1993) found that the
variant with the missing exon 3 did not show any loss of
wild-type transcriptional activity or DNA binding. This
particular variant may therefore represent a natural
alternatively spliced form of ER that is functional. Proof of
this contention for variant ERs will, however, only come
from functional studies such as evaluation of the response to
hormonal manipulation in those patients in whom variant
ERs are detected. In this regard, PCR analysis with nested
primers would appear to be a suitable approach for screening
for such ER variants. It should, however, be pointed out the
four samples in question were all low positive by
immunochemistry, with an average H score of 40. These
cells may no longer have been synthesising ER protein. The
one sample that was analysed as ER mRNA positive but
ERICA negative could have been due to the presence of a
mutation affecting the expression of the ER protein. Again
further examination of the ER gene by PCR should be done
to investigate this possibility. The PCR technique for
examining expression of ER mRNA may therefore also
provide a good screening method for detection of mutations.
The potential usefulness of PCR for the detection ofTGF-
,B mRNA expression in breast cancer cells is confirmed by the
results of the comparison between PCR and immunocyto-
chemistry showing sensitivity and specificity of 100%.
Although the significance of TGF-,B expression in breast
cancer has not been fully elucidated, the role of TGF-,B as a
negative growth regulator for hormone-sensitive breast cancer
derived cell lines has been established in vitro (Knabbe et al.,
1987). Whether this model is applicable to in vivo human
breast cancer, remains to be established and a reliable,
sensitive method for detecting the transcription of the gene
for this growth factor would appear to be extremely useful
for such studies.
While PCR can perpetuate and exponentially amplify even
minute errors in the templates it appears to be a viable
technique for analysis of both ER and TGF-,B. Only a small
sample of material is required for analysis (as few as 1000
cells), it is a rapid technique and subjective interpretation
errors and interobserver variations, which occur in immuno-
cytochemical techniques, can be avoided.
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